Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the diskus® dry powder inhaler

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 3, 2013, Pages 174-179

  Mahler, Donald A ^a   Waterman, Laurie A ^a   Gifford, Alex H ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

advanced COPD; clinical phenotype; dry powder inhaler; test retest reliability

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DRY POWDER INHALER; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PEAK INSPIRATORY FLOW; PHENOTYPE; PREVALENCE; SPIROMETRY;

AGE FACTORS; AGED; BODY HEIGHT; COHORT STUDIES; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INSPIRATORY CAPACITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SEX FACTORS; SPIROMETRY; VITAL CAPACITY;

EID: 84878405695     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.0987     Document Type: Article

References (27)

1. Celli BR, MacNee W, and ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
2. 2011 Global Initiative for Chronic Obstructive Lung Disease; pp. 1-74, 2012. Available at http://www.goldcopd.org. Accessed August 21, 2012.
3. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schunemann H, Wedzicha W, MacDonald R, and Shekelle P: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
4. Atkins PJ: Dry powder inhalers: an overview. Respir Care. 2005;50:1304-1312.
5. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, and Chrystyn H: Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395-2401.
6. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philips T, Troosters T, and Decramer M: Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31:78-83.
7. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, and Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084-1091.
8. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, and Shah T: The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003; 124:834-843.
9. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, Menjoge SS, Serby CW, and Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19:217-224.
10. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Igbal A, Swales J, Owen R, Higgins M, and Kramer B: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
11. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, and Kramer B, and INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators: Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.
12. Jarvis S, Ind PW, and Shiner RJ: Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007; 36:213-218.
13. Han MK, Wise R, Mumford J, Sciurba F, Criner GJ, Curtis JL, Murray S, Sternberg A, Weinman G, Kazerooni E, Fishman AP, Make B, Hoffman EA, Mosenifar Z, and Martinez FJ: Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J. 2010;35: 1048-1056.
14. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, and Keston S: Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742-750.
15. Hankinson JL, Odencrantz JR, and Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-187.
16. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: General considerations for lung function testing. Eur Respir J. 2005;26:153-161.
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: Standardisation of spirometry. Eur Respir J. 2005;26: 319-338.
18. Crapo RO, Morris AH, Clayton PD, and Nixon CR: Lung volumes in healthy nonsmoking adults. Bull Eur Physiopath Respir. 1982;18:419-425.
19. van der Palen J: Peak inspiratory flow through Diskus and Turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respir Med. 2003;97:285-289.
20. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaer T, and Chrystyn H: ERS/ISAM task force report: what the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308-1331.
21. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, and Gil EG: Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103:1832-1837.
22. Bauer A, Holt J, Stewart E, Choudhuri SD, Karafilidis J, and Walsh J: In vitro analysis of the effect of air flow rate on the aerosol properties of nebulized arformoterol and tiotropium and fluticasone/salmeterol delivered via dry powder inhalers. Am J Resp Crit Care Med. 2011;183:A1601.
23. Dewar MH, Jamieson A, McLean A, and Crompton GK: Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med. 1999;93:342-344.
24. GlaxoSmithKline. Advair Diskus. Available at http://www. advair.com. Accessed August 21, 2012.
25. Merck. Foradil Aerolizer. Available at http://www.foradil .us. Accessed August 21, 2012.
26. Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, and Rietveld I: Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26:2527-2533.
27. O'Donnell DE, and Webb KA: Mechanisms of dyspnea in COPD. In: Mahler DA, and O'Donnell DE, (eds). Dyspnea: Mechanisms, Measurement, and Management. Taylor & Francis, New York; pp. 29-58, 2005.